Overview

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

The Hospital for Sick Children

Collaborators:

Multiple Sclerosis Society of Canada
Ontario Institute for Regenerative Medicine
Queen's University
Stem Cell Network
Unity Health Toronto

Treatments:

Metformin